Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Consensus Rating of “Moderate Buy” by Brokerages

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) has been assigned an average rating of “Moderate Buy” from the five research firms that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $10.00.

A number of analysts have recently weighed in on the stock. StockNews.com upgraded shares of Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Monday, November 11th. Truist Financial boosted their target price on shares of Amneal Pharmaceuticals from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Wednesday, October 2nd. Piper Sandler raised their price target on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an “overweight” rating in a research report on Monday, November 11th. JPMorgan Chase & Co. raised Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 price objective for the company in a research report on Friday, September 6th. Finally, Barclays lifted their price target on Amneal Pharmaceuticals from $8.00 to $10.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 13th.

Insider Buying and Selling

In other Amneal Pharmaceuticals news, SVP Jason B. Daly sold 43,657 shares of Amneal Pharmaceuticals stock in a transaction on Friday, November 15th. The shares were sold at an average price of $8.61, for a total transaction of $375,886.77. Following the sale, the senior vice president now owns 13,665 shares in the company, valued at $117,655.65. The trade was a 76.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 26.56% of the stock is owned by company insiders.

Hedge Funds Weigh In On Amneal Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in AMRX. Rothschild Investment LLC acquired a new position in Amneal Pharmaceuticals in the second quarter worth about $26,000. Gladius Capital Management LP acquired a new position in shares of Amneal Pharmaceuticals in the 3rd quarter worth approximately $37,000. DekaBank Deutsche Girozentrale bought a new position in shares of Amneal Pharmaceuticals during the 2nd quarter worth approximately $42,000. nVerses Capital LLC acquired a new stake in Amneal Pharmaceuticals in the 2nd quarter valued at $62,000. Finally, Bayesian Capital Management LP bought a new stake in Amneal Pharmaceuticals in the first quarter valued at $65,000. 31.82% of the stock is owned by institutional investors.

Amneal Pharmaceuticals Stock Performance

Shares of AMRX stock opened at $8.39 on Wednesday. The company has a market capitalization of $2.60 billion, a price-to-earnings ratio of -12.34 and a beta of 1.17. The stock’s 50 day simple moving average is $8.57 and its 200 day simple moving average is $7.73. Amneal Pharmaceuticals has a twelve month low of $4.16 and a twelve month high of $9.48.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.